Piedmont Cancer Institute - Fayetteville

Piedmont Cancer Institute, PC (formerly Peachtree Hematology-Oncology Consultants, PC) physicians are specialists in the treatment and prevention of cancer and blood disorders. The treatment philosophy includes the approach that during the healthcare experience at Piedmont Cancer Institute, PC, physicians are partners with the patient. The practice provides patients and their families with the most current medical knowledge and treatment available; education about your specific treatment; psychological and emotional support; access to community resources and support groups; and access to clinical trials and research protocols. The center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers.

Treatment Sites in Georgia

Primary Location

1267 Highway 54 West
Suite 4200
Fayetteville, GA 30214
678-829-1060 (p)
678-829-1099 (f)
www.piedmontcancerinstitute.com

driving directions

Clinical Trials in Georgia

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease
Cancer Type: Breast Cancer, Melanoma

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Cancer Type: Unknown Primary
Study Coordinator: Ann Johnston - 678-298-3235


A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Cancer Type: Liver Cancer
Study Coordinator: Ann Johnston - 678-298-3235


A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery
Cancer Type: Breast Cancer

A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).
Cancer Type: Colon/Rectal Cancer
Study Coordinator: Ann Johnston - 678-298-3235


A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study)
Cancer Type: Breast Cancer
Study Coordinator: Ann Johnston - 678-298-3235


A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Ann Johnston - 678-298-3235


A Randomized, Open-Label, Multicenter Study of Eribulin Mesylate in Combination with PEGylated Recombinant Human Hyaluronidase (PEGPH20) versus Eribulin Mesylate Alone in Subjects with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Ann Johnston - 678-298-3235


An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602
Cancer Type: Multiple Myeloma
Study Coordinator: Ann Johnston - 678-298-3235


Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Cancer Type: Lung Cancer
Study Coordinator: Ann Johnston - 678-298-3235